Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents

ACS Medicinal Chemistry Letters

Volumn 5, Issue 5, 2014, Pages 609-614

  Singh, Sheo B ^a,d   Kaelin, David E ^a   Wu, Jin ^a   Miesel, Lynn ^a   Tan, Christopher M ^a   Meinke, Peter T ^a   Olsen, David ^a   Lagrutta, Armando ^a   Bradley, Prudence ^a   Lu, Jun ^a   Patel, Sangita ^a   Rickert, Keith W ^a   Smith, Robert F ^a   Soisson, Stephen ^a   Wei, Changqing ^b   Fukuda, Hideyuki ^c   Kishii, Ryuta ^c   Takei, Masaya ^c   Fukuda, Yasumichi ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b WUXI APPTEC   (China)

^c KYORIN PHARMACEUTICAL CO LTD   (Japan)

^d SBS Pharma Consulting LLC   (United States)

Author keywords

Antibacterial; broad spectrum; gyrase inhibitors; NBTI; novel bacterial topoisomerase inhibitors; oxabicyclooctane; topoisomerase IV inhibitors

Indexed keywords

AM 8191; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE INHIBITOR; GSK 299423; OXABICYCLOOCTANE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; DNA SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 84900404249     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500069w     Document Type: Article

References (17)

1. Klevens, R. M.; Morrison, M. A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L. H.; Lynfield, R.; Dumyati, G.; Townes, J. M.; Craig, A. S.; Zell, E. R.; Fosheim, G. E.; McDougal, L. K.; Carey, R. B.; Fridkin, S. K. Invasive methicillin-resistant Staphylococcus aureus infections in the United States J. Am. Med. Assoc. 2007, 298, 1763-1771
2. Zhanel, G. G.; DeCorby, M.; Adam, H.; Mulvey, M. R.; McCracken, M.; Lagace-Wiens, P.; Nichol, K. A.; Wierzbowski, A.; Baudry, P. J.; Tailor, F.; Karlowsky, J. A.; Walkty, A.; Schweizer, F.; Johnson, J.; Canadian Antimicrobial Resistance Alliance; Hoban, D. J. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008) Antimicrob. Agents Chemother. 2010, 54, 4684-4693
3. Bisacchi, G. J.; Dumas, J. Recent advances in the inhibition of bacterial type II topoisomerases Annu. Rep. Med. Chem. 2009, 44, 379-396
4. Mayer, C.; Janin, Y. L. Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism Chem. Rev. 2014, 114, 2313-2342
5. Bax, B. D.; Chan, P. F.; Eggleston, D. S.; Fosberry, A.; Gentry, D. R.; Gorrec, F.; Giordano, I.; Hann, M. M.; Hennessy, A.; Hibbs, M.; Huang, J.; Jones, E.; Jones, J.; Brown, K. K.; Lewis, C. J.; May, E. W.; Saunders, M. R.; Singh, O.; Spitzfaden, C. E.; Shen, C.; Shillings, A.; Theobald, A. J.; Wohlkonig, A.; Pearson, N. D.; Gwynn, M. N. Type IIA topoisomerase inhibition by a new class of antibacterial agents Nature 2010, 466, 935-940
6. Wiener, J. J.; Gomez, L.; Venkatesan, H.; Santillan, A., Jr.; Allison, B. D.; Schwarz, K. L.; Shinde, S.; Tang, L.; Hack, M. D.; Morrow, B. J.; Motley, S. T.; Goldschmidt, R. M.; Shaw, K. J.; Jones, T. K.; Grice, C. A. Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains Bioorg. Med. Chem. Lett. 2007, 17, 2718-2722
7. Black, M. T.; Stachyra, T.; Platel, D.; Girard, A. M.; Claudon, M.; Bruneau, J. M.; Miossec, C. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases Antimicrob. Agents Chemother. 2008, 52, 3339-3349
8. Black, M. T.; Coleman, K. New inhibitors of bacterial topoisomerase GyrA/ParC subunits Curr. Opin. Invest. Drugs 2009, 10, 804-810
9. Gomez, L.; Hack, M. D.; Wu, J.; Wiener, J. J.; Venkatesan, H.; Santillan, A., Jr.; Pippel, D. J.; Mani, N.; Morrow, B. J.; Motley, S. T.; Shaw, K. J.; Wolin, R.; Grice, C. A.; Jones, T. K. Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis Bioorg. Med. Chem. Lett. 2007, 17, 2723-2727
10. Miles, T. J.; Axten, J. M.; Barfoot, C.; Brooks, G.; Brown, P.; Chen, D.; Dabbs, S.; Davies, D. T.; Downie, D. L.; Eyrisch, S.; Gallagher, T.; Giordano, I.; Gwynn, M. N.; Hennessy, A.; Hoover, J.; Huang, J.; Jones, G.; Markwell, R.; Miller, W. H.; Minthorn, E. A.; Rittenhouse, S.; Seefeld, M.; Pearson, N. Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases Bioorg. Med. Chem. Lett. 2011, 21, 7489-7495
11. Miles, T. J.; Barfoot, C.; Brooks, G.; Brown, P.; Chen, D.; Dabbs, S.; Davies, D. T.; Downie, D. L.; Eyrisch, S.; Giordano, I.; Gwynn, M. N.; Hennessy, A.; Hoover, J.; Huang, J.; Jones, G.; Markwell, R.; Rittenhouse, S.; Xiang, H.; Pearson, N. Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases Bioorg. Med. Chem. Lett. 2011, 21, 7483-7488
12. Mitton-Fry, M. J.; Brickner, S. J.; Hamel, J. C.; Brennan, L.; Casavant, J. M.; Chen, M.; Chen, T.; Ding, X.; Driscoll, J.; Hardink, J.; Hoang, T.; Hua, E.; Huband, M. D.; Maloney, M.; Marfat, A.; McCurdy, S. P.; McLeod, D.; Plotkin, M.; Reilly, U.; Robinson, S.; Schafer, J.; Shepard, R. M.; Smith, J. F.; Stone, G. G.; Subramanyam, C.; Yoon, K.; Yuan, W.; Zaniewski, R. P.; Zook, C. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV Bioorg. Med. Chem. Lett. 2013, 23, 2955-2961
13. Miles, T. J.; Hennessy, A. J.; Bax, B.; Brooks, G.; Brown, B. S.; Brown, P.; Cailleau, N.; Chen, D.; Dabbs, S.; Davies, D. T.; Esken, J. M.; Giordano, I.; Hoover, J. L.; Huang, J.; Jones, G. E.; Sukmar, S. K.; Spitzfaden, C.; Markwell, R. E.; Minthorn, E. A.; Rittenhouse, S.; Gwynn, M. N.; Pearson, N. D. Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases Bioorg. Med. Chem. Lett. 2013, 23, 5437-5441
14. Reck, F.; Alm, R.; Brassil, P.; Newman, J.; Dejonge, B.; Eyermann, C. J.; Breault, G.; Breen, J.; Comita-Prevoir, J.; Cronin, M.; Davis, H.; Ehmann, D.; Galullo, V.; Geng, B.; Grebe, T.; Morningstar, M.; Walker, P.; Hayter, B.; Fisher, S. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity J. Med. Chem. 2011, 54, 7834-7847
15. a: antibacterial agents with an improved safety profile J. Med. Chem. 2012, 55, 6916-6933
16. Surivet, J. P.; Zumbrunn, C.; Rueedi, G.; Hubschwerlen, C.; Bur, D.; Bruyere, T.; Locher, H.; Ritz, D.; Keck, W.; Seiler, P.; Kohl, C.; Gauvin, J. C.; Mirre, A.; Kaegi, V.; Dos Santos, M.; Gaertner, M.; Delers, J.; Enderlin-Paput, M.; Boehme, M. Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity J. Med. Chem. 2013, 56, 7396-7415
17. Phillips, J. W.; Goetz, M. A.; Smith, S. K.; Zink, D. L.; Polishook, J.; Onishi, R.; Salowe, S.; Wiltsie, J.; Allocco, J.; Sigmund, J.; Dorso, K.; Lee, S.; Skwish, S.; de la Cruz, M.; Martin, J.; Vicente, F.; Genilloud, O.; Lu, J.; Painter, R. E.; Young, K.; Overbye, K.; Donald, R. G.; Singh, S. B. Discovery of kibdelomycin, a potent new class of bacterial type II topoisomerase inhibitor by chemical-genetic profiling in Staphylococcus aureus Chem. Biol. 2011, 18, 955-965